- Resource
- Source: Campus Sanofi
- 23 Oct 2023
Praluent® (alirocumab) Patient profiles
Second MI
6 weeks ago
Age: 55 years
LDL-C: 3.6 mmol/L
Polyvascular disease (CAD & PAD)
Smoker
First MI
6 months ago
Age: 63 years
LDL-C: 4.1 mmol/L
No additional comorbidities or family history of heart disease
Non-smoker
First MI
12 months ago
Age: 63 years
LDL-C: 5.0 mmol/L
Familial hypercholesterolaemia
Non-smoker
Any ACS means the patient is at very high CV risk, regardless of comorbidities1
References
- March F, et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias; lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188.
MAT-XU-2204602 (v7.0) Date of Preparation: February 2024